Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Grant A. McArthur(The University of Melbourne), John M. Kirkwood(UPMC Hillman Cancer Center), John B.A.G. Haanen(Leiden University Medical Center), Michele Maio(University of Siena), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Keith T. Flaherty(Cancer Research Center), Célèste Lebbé(Inserm), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Richard J. Lee(La Roche College), Axel Hauschild(University Hospital Schleswig-Holstein), Thomas Jouary(Hôpital Saint-André), Alexander M.M. Eggermont(University Medical Center Utrecht), Steven O’Day(Saint John's Health Center), David Hogg(University of Leeds), Paul Lorigan(Manchester Academic Health Science Centre), B. Nelson, Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), James Larkin(Trinity College Dublin), Antoni Ribas(University of California, Los Angeles), Reinhard Dummer(University Hospital of Zurich), Jiang Li(Jiangxi Provincial People's Hospital), Caroline Robert(Institut Gustave Roussy), K. B. Nolop(Plexxikon (United States)), Claus Garbe(University of Tübingen), Jeannie Hou, Brigitte Dréno(Nantes Université)
Cited by 7,685
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k